No abstract available
Keywords:
heart failure; hospitalization; prognosis; sacubitril-valsartan; systems biology.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aminobutyrates / adverse effects
-
Aminobutyrates / therapeutic use*
-
Angiotensin II Type 1 Receptor Blockers / adverse effects
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
-
Biphenyl Compounds
-
Disease Progression
-
Drug Combinations
-
Heart Failure / diagnostic imaging
-
Heart Failure / drug therapy*
-
Heart Failure / mortality
-
Heart Failure / physiopathology
-
Hospitalization
-
Humans
-
Neprilysin / antagonists & inhibitors
-
Protease Inhibitors / adverse effects
-
Protease Inhibitors / therapeutic use*
-
Recovery of Function
-
Tetrazoles / adverse effects
-
Tetrazoles / therapeutic use*
-
Time Factors
-
Treatment Outcome
-
Valsartan
-
Ventricular Function, Left / drug effects*
-
Ventricular Remodeling / drug effects*
Substances
-
Aminobutyrates
-
Angiotensin II Type 1 Receptor Blockers
-
Biphenyl Compounds
-
Drug Combinations
-
Protease Inhibitors
-
Tetrazoles
-
Valsartan
-
Neprilysin
-
sacubitril and valsartan sodium hydrate drug combination